Epic Sciences

Custom Biomarker Development

We utilize our proprietary single cell CTC platform to develop blood based biomarkers for solid tumor indications with our pharma partners. Measurability is determined by analyzing a patient cohort for:

  1. CTC prevalence
  2. CTC phenotypes/genotypes
  3. Heterogeneity of phenotypes/genotypes
  4. Associations between specific CTC subtypes and therapeutic responses at decision points and throughout care


The flow diagram (left panel) describes the stepwise biomarker development process and specific tools employed to develop a custom biomarker utilizing Epic Sciences’ proprietary CTC platform. Key questions to be addressed by translational researchers (middle) and the tools used (right) are shown in the figure.

Contact Us to Discuss Custom Biomarker Development

Contact/Request Form


If you are a physician, please do not leave any patient information. 

Customer service is available Monday through Friday from 8am to 5pm Pacific time.